The level of LRG1 obtained from eyes in patients with neovascular age-related macular degeneration were increased, which indicated the target therapeutic therapy of anti-LRG1 monoclonal antibody (Mundo et al., 2021). Here, LRG1 is linked to wet macular degeneration.